Girindus signs up to Adolor development deal

Published: 29-Jun-2001


German company Girindus has signed a Phase III API qualification milestone for up to US$3.2m with US biopharmaceutical company Adolor.

Girindus is to manufacture demonstration batches, prepare NDA documentation and scale-up and manufacture validation batches in accordance with cGMP for Adolor's investigational peripheral µ-opioid antagonist.

The drug candidate, which has already entered into Phase III trials, is designed to block the adverse GI side-effects of morphine and other narcotic analgesics without blocking their beneficial pain-relieving effects.

The milestones should be complete by the end of April 2002. Subject to FDA approval and other conditions, at least six months before the completion of the milestones, the companies may enter into a multimillion-dollar commercial supply agreement.

You may also like